Successful Treatment of Autoimmune Hemolytic Anemia with Steroid, IVIg, and Plasmapheresis in a Haploidentical Transplant Recipient
Journal Title: Turkish Journal of Hematology - Year 2012, Vol 29, Issue 2
Abstract
To the Editor, Autoimmune hemolytic anemia (AIHA) is a rare, but clinically significant complication following hematopoietic stem cell transplantation (HSCT). It is characterized by hemolysis due to antibodies produced by the donor’s immune system against donor red cell antigens. The 3-year cumulative incidence of AIHA is 4.44% in adults; however, 75% of patients develop AIHA during the first post-HSCT year [1]. AIHA after allogeneic HSCT has been associated with a variety of conditions, including chronic graft-versus-host disease (GVHD) [2], T-cell depletion [3], and unrelated donor transplants [4]. HSCT from unrelated donors and the development of chronic extensive GVHD were the only independent factors associated with AIHA [1]; however, the incidence of and risk factors for AIHA, as well as its prognosis and response to treatment remain unclear.
Authors and Affiliations
Burak Uz, Evren Özdemir, Salih Aksu, Tülay Akyol, Roy Jones
H1N1 Enfeksiyonu ile İlişkili Hemofagositik Lenfohistiositoz Saptanan Bir Çocuk Hasta
Kazanılmış Hemofilinin Immunsupresif ve Immunadsorbsiyon Kombinasyonu ile Tedavisi
Doğum Sonrası Kazanılmış Faktör VIII İnhibitörü ve Steroid Tedavisi
Acute Myocardial Infarction Due to Eltrombopag Therapy in a Patient with Immune Thrombocytopenic Purpura
Acute Myocardial Infarction Due to Eltrombopag Therapy in a Patient with Immune Thrombocytopenic Purpura
Successful Treatment of Autoimmune Hemolytic Anemia with Steroid, IVIg, and Plasmapheresis in a Haploidentical Transplant Recipient
To the Editor, Autoimmune hemolytic anemia (AIHA) is a rare, but clinically significant complication following hematopoietic stem cell transplantation (HSCT). It is characterized by hemolysis due to antibodies produced...